All timings shown are UK BST
John has a strong background and reputation in the European e-cigarette industry having held senior executive positions in some of the US and Europe’s biggest companies. He advises many leading industry analysts, financial institutions and media organisations looking at the vaping and CBD sectors. John is also one of the founders of the UKVIA , the UK’s largest vaping Industry association and has advised the UK governments All Party Parliamentary Group on Vaping as well as giving evidence before the UK Science & Technology Committee investigation into the Vaping industry and the Australian Parliaments review on vaping. John is a regular guest speaker at many of the worlds leading conventions. John regularly appears on national and international television stations and print media to discuss vaping related matters.
Nigel R Quine
Founder of Cuts Ice Limited.
Co-Founder of Flavour Core Limited.
Co-Founder of IBVTA (Independent British Vape Trade Association).
Co-Founder of IEVA (Independent European Vape Alliance).
10 years working in the vape industry, developing standards and a sensible regulatory framework for the sector.
Pioneering the development of ‘vape grade’ products and the safety of flavours in ENDS.
Investor in the independent vape channel, promoting specialist retail as the most effective provider of smoking cessation services which keep smokers off harmful combustible products.
Tim Phillips is managing director of ECigIntelligence, the leading source of independent data for the e-cigarette and vaping sector globally, providing unbiased information to numerous leading international companies together with government regulators such as the FDA and the UK government. He is also managing director of a sister publication, CBD-Intel, which is a business intelligence service providing professional, independent market analysis and regulatory tracking for the growing cannabidiol sectors worldwide.
He is a U.K.-qualified attorney, having worked at the European Commission, Herbert Smith, BSkyB, AOL Europe, and as director of public affairs at Betfair as it went through its £1.5bn IPO in 2010. He was also a partner in a New York venture capital-funded startup in the diamond sector. Phillips qualified as a lawyer at the College of Law, London, and holds an MA in Geology from Oxford University.
Ian is an independent consultant with expertise in regulatory and scientific aspects of nicotine and tobacco products. Ian most recently worked for JUUL Labs as Senior Director of Clinical and Regulatory Affairs EMEA, and previously he was Director of Tobacco Research at Celerion, a provider of clinical research capabilities and expertise to the tobacco and e-cigarette industry. Prior to that, Ian was Principal Scientist and Head of Clinical Research at British American Tobacco's central research and development centre in Southampton, U.K. He specializes in the biological and psychological effects of nicotine, clinical and pre-clinical studies to assess the biological effects of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation. Prior to working in the industry, Ian pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor in Biology at McMaster University in Hamilton, Canada. Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers and book chapters which have generated over 2,400 citations.
Rob de Lange chairs Acvoda, the Dutch non-profit organisation which supports Harm Reduction alternatives for consumers, since 2018. Acvoda strives to inform consumers on the risks and benefits of Harm Reduction alternatives to smoking, based on unbiased , peer reviewed studies and scientific research. Mr. de Lange holds the view that only truth based factual information can withstand scrutiny and form a formidable defence against inappropriate regulations and non Harm Reduction based Tobacco regulating ideologies.
As Acvoda’s chair, he holds meetings with consumers, scientists, researchers and policy-makers and acts as a liaison for the Dutch e-cigarette trade organisation, as well as writing various media articles on Harm Reduction. With various certifications in IT-security, Mr. de Lange is well equipped to discern facts from fiction.
Rob de Lange was appointed president of INNCO in 2021.
Over 30 years’ industry experience both in research & development, regulatory preclinical work & toxicological risk assessment. Director of preclinical toxicology & pharmacology at a CRO for 13 years. Senior Toxicologist/Toxicology Manager at several FMCG companies under the Product Stewardship department, supporting the next Generation Products by advising the company on the Quantitative Risk Assessment procedure under current regulations, the testing strategy for innovative products to ensure their safe commercialization, liaising with external advisors, engaging with regulators & communicating & presenting projects/strategies to internal stakeholders.
Thorough understanding & knowledge of the regulatory pre-requisites for preclinical testing, having put together many preclinical study packages for a large diversity of pharmaceutical compounds with diverse routes of administration & applications (inflammation, pulmonary, gastrointestinal, CNS, etc), including biotechnology-derived products & advanced therapies such as cellular therapy & genetic therapy products, as well as consumer products (oral & inhalation). Carried out toxicological risk-assessment & exposure evaluations for numerous consumer products, including specific assessments of food additives, flavourings & chemicals according to ECHA REACH Technical Guidance. Acted as Expert Advisor to the EC on the 7th Framework Program (FP7), as well as presently under the Eurostars (EUREKA) programme.